Na+ channel blocker: Na+ channel block depends on: HR

Slides:



Advertisements
Similar presentations
Antiarrhythmic Drugs.
Advertisements

TACHYCARDIAS Dr Kirsten Cohen
Antiarrhythmic drugs.
Or Doing Drugs for Your Heartbeat
Anti-arrhythmic drugs
Mechanisms of cardiac arrhythmias
ANTIARRHYTHMIC DRUGS Arrhythmia or dysrhythmia means an abnormal or irregular heart beat Arrhythmias may originate in the atria, SA node or AV node, whereby.
Pharmacology I Drugs Used to Treat Arrhythmias. Arrhythmias Needing Treatment: Atrial Fibrillation/Flutter (AF) Supraventricular Tachycardia (SVT) Ventricular.
ANTIARRHYTHMIC DRUGS Arrhythmia/ dysrhythmia means an abnormal or irregular heart beat Arrhythmias may originate in the atria, SA node or AV node, whereby.
October 6, 2006 Frank F. Vincenzi
Cardiac Arrhythmias.
Drugs used to treat cardiac arrhythmias
CARDIAC ARRHYTHMIA.
Arrhythmia Arrhythmias are abnormal beats of the heart.
Antiarrhythmic Drugs.
Anti-arrhythmic drugs
Anti arrhythmic Drugs Marwa A. Khairy , MD.
Antiarrhythmic drugs Pharma team.
Clinical Use of Antiarrhythmic Agents
Cardio-vascular Pharmacology By Professor Doctor: Abd Al Rahman Abd Al Fattah Yassin Professor and head of clinical pharmacology department Mansura university.
ANTIARRHYTHMIC DRUGS 1. INTRODUCTION The heart contains specialized cells that exhibit automaticity; that is, they can generate rhythmic action potentials.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 49 Antidysrhythmic Drugs.
Agents used to treat Arrhythmias Dr. Thomas Abraham PHAR417: Fall 2005.
ANTIARRHYTHMIC DRUGS Department of Pharmacology and Toxicology
© Assoc. Prof. Ivan Lambev
Section 3, Lecture 4 Antiarrhytmic drugs cont…
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 23 Antiarrhythmic Drugs.
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE Faculty of Medicine, The University of Jordan The University of Jordan October 2014.
Antidysrhythmic Drugs
Arrhythmias and Antiarrhythmic Drugs
Supraventricular Arrhythmias Claire B. Hunter, M.D.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 23 Antidysrhythmic Drugs.
Chapter 17 Cardiac Stimulants and Depressants. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved
Circus Movement Classification of antiarrhythmic drugs According to Vaughn-Williams Classification: Class 1: Sodium channel blockersClass 1: Sodium.
Antiarrhythmic Agents. BACKGROUND Inside cell: K + ; Outside cell: Na +, Ca + +, Cl - Action potential (AP) and Phase 0-4 phase0---reactivity---conduction---
ANTIARRHYTHMIC DRUGS 1. INTRODUCTION The heart contains specialized cells that exhibit automaticity; that is, they can generate rhythmic action potentials.
Cardiovascular pharmacology.
4-ANTIARRHYTHMIC DRUGS
Drugs for Arrhythmias.
By Ali alalawi. Arrhythmia  Cardiac arrhythmia (also dysrhythmia) is a term for any of a large and heterogeneous group of conditions in which there is.
Calcium Channel Blockers and Digitalis. Dig Ca Channel Blockers.
BIMM118 Cardiac Arrhythmia Arrhythmias : Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: –when the heart’s.
Antiarrhythmic Drugs Dr. Tom Murray Department of Pharmacology.
23 Antiarrhythmic Drugs.
Antiarrhythmic Drugs. Drug List Class 1 Sodium Channel Blockers Class 2 Beta-blockers Class 3 Potassium Channel blockers Class 4 Calcium Channel Blockers.
ANTI-ARRHYTHMIC DRUGS
Cardiac Arrhythmia.
Anti arrhythmic drugs Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab.DCA, Dip. Software statistics, Phd (physio) Mahatma Gandhi Medical college.
Pharmacology 4 Dr. Khalil Makki. Antiarrhythmic Drugs.
Prof. Abdulrahman Almotrefi
* QUINIDINE  Quinidine has pronounced cardiac anti muscarinic effects. It is absorbed orally. It undergoes extensive metabolism by the hepatic cytochrome.
Antiarrhythmic Drugs.
Dept. of Pharmacology Faculty of Medicine AIMST
ARRHYTHMIAS Jamil Mayet. Arrhythmias - learning objectives –Mechanisms of action of antiarrhythmic drugs –Diagnosis To differentiate the different types.
Cardiovascular Cardiovascular pharmacology pharmacology.
CODE BLUE MANAGEMENT DRUG THERAPY
Anti arrhythmic drugs.
Anti-arrhythmic drugs
Antidysrhythmic Agents
Cariovascular pharmacology for primary care physician: cardiotonics, antiarrhytmics, vasodilatators Domina Petric, MD.
Antiarrhythmic Drugs 7/28/2018.
Treatment of Congestive Heart Failure
Dr.mojiri Pharm-D Pharmacologist
CARDIAC ARRHYTHMIAS & ANTI-ARRHYTHMIC DRUGS
Review of Cardiovascular and Renal Drugs
Antiarrhythmic drugs [,æntiə'riðmik] 抗心律失常药
Chapter 30 Antiarrhythmic Drugs
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family.
Drugs used in the treatment of arrhythmia I
Presentation transcript:

Na+ channel blocker: Na+ channel block depends on: HR Membrane potential Drug specific physiochemical characteristic-  recovery Blockade of Na+ channels results in: Threshold for excitability is increased (more current) Increase in pacing and defibrillation threshold Decrease conduction velocity in fast response tissues Increase QRS interval (due to conduction slowing in ventricles) Some drugs tend to prolong PR interval- flecainide (possibly Ca2+ channel blockade)

Some sodium channel blockers shorten the PR interval (quinidine; vagolytic effect) APD unaffected or shortened Increase in threshold for excitation also decreases automaticity Can also inhibit DAD/EAD Delays conduction so can block re-entry In some cases, it can exacerbate re-entry by delaying conduction Shift voltage dependence of recovery of sodium channels from inactivated state to more negative potentials and so increases refractoriness Net effect- whether it will suppress or exacerbate re-entry arrhythmia depends on its effect on both factors- conduction velocity and refractoriness

Most Na+ channel blockers bind to either open or inactivated state and have very little affinity for channels in closed state, drug binds to channels during systole & dissociates during diastole ADRs: Decrease in conduction rate in atrial flutter- slows rate of flutter and increases HR due to decrease in AV blockade Especially common with quinidine due to its vagolytic property; also seen with flecainide and propafenone Cases of ventricular tachycardia due to re-entrant rhythm following MI may worsen due to slowing of conduction rate Slowing of conduction allows the re-entrant rhythm to persist within the circuit so that complicated arrhythmias can occur Several Na+ channel blockers have been reported to exacerbate neuromuscular paralysis by d-tubocurarine

Na+ channel blockers lidocaine, phenytoin and mexiletine have only sodium channel blocking activity Lidocaine blocks Na+ channels more in open than in inactive state Phenytoin blocks them in inactivated state Quinidine blocks Na+ channels in open state It also has vagolytic and  blocking activity Procainamide, disopyramide, propafenone block sodium channels in open state Sotalol is a  blocker with Na+ channel blocking activity Amiodarone and dronedarone block sodium channels in inactivated state and produce non-competitive blockade of  receptors

Phenytoin is an anti-epileptic drug that blocks sodium channels and is used for treatment of digitalis induced tachyarrhythmias Reasons: Does not aggravate AV block Does not produce hypotension It is a potent hepatic microsomal enzyme inducer Toxicity- gum hyperplasia Mexiletine is an oral analogueof lidocaine, does not undergo first pass metabolsm It is preferred for treatment of ventricular arrhythmias associated with previous MI Lidocaine, a local anaesthetic is given as i.v. loading dose of 150-200 mg in 15 min followed by maintenance dose

Lidocaine is extensively metabolized in the liver so not given orally Toxicity- drowsiness, convulsions, slurred speech, confusion, paresthesia Quinidine, due to vagolytic action, can potentiate ventricular tachycardia if given in the presence of rapid heart rate In addition to antiarrhythmic effect, it has antimalarial, antipyretic and skeletal muscle relaxant actions Procainamide is a derivative of procaine, a LA with actions similar to that of quinidine

Quinidine is contraindicated in cases of: AV block (because it slows conduction) QT prolongation (already slow conduction is there) CHF and hypotension due to its negative inotropic effects Digitalis intoxication and hyperkalemia that potentiate the decrease in conduction velocity by quinidine Digitalis toxicity because it has negative inotropic effects so antagonizes positive inotropic effects of digitalis Myasthenia gravis (may be aggravated due to its muscle relaxant property Atrial flutter & fibrillation (rapid HR)- quinidine can potentiate ventricular tachycardia due to its vagolytic action on AV node

ADRs of quinidine: Diarrhoea Reversible thrombocytopenia due to formation of plasma protein-quinidine complex which forms antibodies against circulating platelets Quinidine syncope- loss of consciousness due to ventricular arrhythmias) Large doses (toxicity) may cause cinchonism- tinnitus, headache, nausea, blurring of vision and vertigo Interactions: Increases plasma levels of digoxin & precipitates its toxicity Enzyme inducers facilitate its metabolism-  plasma concentration Mg hydroxide & CaCO3 elevate its plasma concentration

K+ Channel blockers: Prolong APD (QT interval) and reduces automaticity Increase in APD also increases refractoriness Effective in treating re-entrant arrhythmias Reduce energy requirement for defibrillation Inhibit ventricular arrhythmias in cases of myocardial ischemia Many K+ channel blockers also have  blocking activity also like sotalol Disproportionate prolongation of APD can result in torsaides de pointes, specially when basal HR is slow

Drugs included in this group are amiodarone, dronedarone, ibutilide, dofetilide, bretylium and sotalol They prolong APD and ERP without affecting phase 0 depolarization or resting membrane potential Amiodarone is an iodine containing analogue of thyroid hormone It is highly lipohilic drug It blocks inactivated Na+ channels, Ca2+ channels and K+channels Bretylium is a adrenergic neurone blocker with K+ channel blocking activity It was introduced as antihypertensive –obsolete now Used i.v. for treatment of resistant ventricular arrhythmias

CCBs: Major effect on nodal tissues Verapamil, diltiazem and bepridil cause slowing of HR, nifedipine and other dihydropyridines reflexly increase HR Decrease AV nodal conduction so PR interval increases AV nodal block occurs due to decremental conduction and increase in AV nodal refractoriness DAD leading to ventricular tachycardia respond to verapamil Verapamil and diltiazem are recommended for treatment of PSVT Bepridil increases APD in many tissues and can exert antiarrhythmic action in atria and ventricles but it use is associated with increased incidence of torsades de pointes- rarely used

Verapamil and diltiazem block both open and inactivated L-type of calcium channels They decrease the rate of phase 4 depolarization in SA and AV nodes decrease conduction in AV node Adenosine: Naturally occuring neucleotide Administered as rapid i.v. bolus for acute termination of re-entrant supraventricular arrhythmias Also used to produce controlled hypotension for some surgical procedures Effects are mediated through G-protein coupled adenosine receptors It activates ACh sensitive K+ current in atrium, SA and AV nodes Shortens APD, hyperpolarization and slowing of automaticity

It also reduces Ca2+ currents and increases nodal refractoriness thereby acts as antiarrhythmic t½ is in seconds Magnesium sulphate: to terminate torsaides de pointes, mechanism unknown

Vernakalant: Blocks several ion channels in atria Mainly blocks ultra rapidly acting delayed rectifier K+ channels Also blocks other K+ currents, Na+ current and L-type of Ca2+ current Does not significantly affect ventricular refractoriness Used for treatment of atrial fibrillation as i.v. infusion